As Zurn Elkay Water Solutions prepares to report its quarterly results, investors are watching to see if the company can extend its impressive track record of exceeding revenue forecasts. We break down the key figures, peer performance, and market sentiment heading into the announcement.
While major indices grapple with uncertainty, a search for value is leading some investors to overlooked companies with strong fundamentals. We examine three such firms from Taiwan and Japan that are posting impressive growth despite sector headwinds.
Singapore will establish its National Space Agency on April 1st, aiming to leverage its technological prowess to secure a strategic position in the rapidly expanding global space economy, as global investments continue to soar.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
IonQ, a pioneer in trapped-ion quantum computing, has seen its stock soar on the back of significant technical breakthroughs. Yet, with a valuation eclipsing established giants and a long road to commercial viability, investors face a high-stakes gamble between revolutionary potential and financial reality.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Advanced Energy Industries (AEIS) transitions from the S&P 600 to the S&P 400 index, a move that reflects its evolving market stature and is set to alter its visibility among institutional investors and index-tracking funds.
Following a series of brazen, coordinated attacks claimed by a separatist group that killed dozens, Pakistani security forces report a sweeping response resulting in over 140 militant casualties, as tensions with neighboring India and Afghanistan flare.
Aalberts N.V. (AMS:AALB), a mid-cap specialist in industrial technology, has seen a significant price surge on the ENXTAM, prompting analysts to revisit its valuation and growth trajectory amidst market volatility.
A deep-dive valuation using a Discounted Cash Flow model suggests Avolta AG's shares are trading close to their intrinsic fair value. We break down the assumptions, the numbers, and the critical factors investors should consider beyond the model.
In a targeted night operation in Borno state, Nigerian troops neutralized a high-ranking Boko Haram leader and ten fighters, marking a significant blow to the militant group's command structure in its historic stronghold.
From Mussolini's Rome-Berlin Axis to Bush's 'Axis of Evil,' the term has evolved from a descriptive label to a powerful political tool, framing global rivalries and shaping diplomatic realities.
As AMETEK prepares to report its quarterly results, investors are watching to see if the electronics manufacturer can maintain its streak of strong performance amid a mixed landscape for industrial equipment firms.
As Merck prepares to release its fourth-quarter results, investors are watching to see if the pharmaceutical leader can maintain its track record of exceeding expectations amid a slowing growth outlook.
As Pfizer prepares to report its fourth-quarter results, investors are weighing the company's strategic pivot beyond its COVID-19 portfolio against a backdrop of expected revenue declines. The report may set the tone for the broader pharmaceutical sector.
As Super Micro Computer (SMCI) prepares to release its quarterly results, the market watches to see if its AI server business can sustain explosive growth and justify its soaring valuation.
Japan's manufacturing activity expanded at its fastest pace since mid-2022 in January, a key private survey shows, driven by robust domestic and international orders. While the sector's revival is clear, rising input costs and inflation concerns temper the optimism.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
